Agenus announces positive preliminary results of inkt cell therapy trial in covid-19

Lexington, mass., feb. 04, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its phase 1 trial of inkt cell therapy in patients with moderate to severe symptoms of covid-19 through its subsidiary, agentus therapeutics.
AGEN Ratings Summary
AGEN Quant Ranking